4.7 Article

Equol status and blood lipid profile in hyperlipidemia after consumption of diets containing soy foods

Journal

AMERICAN JOURNAL OF CLINICAL NUTRITION
Volume 95, Issue 3, Pages 564-571

Publisher

OXFORD UNIV PRESS
DOI: 10.3945/ajcn.111.017418

Keywords

-

Funding

  1. Natural Sciences and Engineering Research Council of Canada
  2. Loblaw Brands Ltd
  3. Heart and Stroke Foundation of Ontario
  4. Orafti Group
  5. Solae, LLC, Loblaw Companies Limited
  6. Federal Government of Canada
  7. Orafti Group (Tienen, Belgium)
  8. Canadian Institutes of Health Research (CIHR)
  9. Unilever
  10. Barilla
  11. Almond Board of California
  12. Solae
  13. Haine Celestial
  14. Sanitarium Company
  15. Orafti
  16. International Tree Nut Council
  17. Peanut Institute
  18. CIHR

Ask authors/readers for more resources

Background: Recent analyses have challenged the effectiveness of soy foods as part of a cardiovascular risk reduction diet. Objective: The objective of the study was to show whether equol status determines the effectiveness of soy foods to lower LDL cholesterol and to raise HDL cholesterol. Design: Eighty-five hypercholesterolemic men and postmenopausal women (42 men, 43 women) participated in 1 of 3 studies that represented a range of soy interventions and that followed the same general protocol at a Canadian university hospital research center. Soy foods were provided for 1 mo at doses of 30-52 g/d for the 3 studies as follows: 1) soy foods with either high-normal (73 mg/d) or low (10 mg/d) isoflavones, 2) soy foods with or without a pre-biotic to enhance colonic fermentation (10 g polyfructans/d), or 3) soy foods with a low-carbohydrate diet (26% carbohydrate). Studies 1 and 2 were randomized controlled crossover trials, and study 3 was a parallel study. Results: The separation of the group into equol producers (n = 30) and nonproducers (n = 55) showed similar reductions from baseline in LDL cholesterol (-9.3 +/- 2.5% and -11.1 +/- 1.6%, respectively; P = 0.834), with preservation of HDL cholesterol and apolipoprotein A-I only in equol producers compared with reductions in nonproducers (HDL cholesterol: +0.9 +/- 2.7% compared with -4.3 +/- 1.1%, P = 0.006; apolipoprotein A-I: -1.0 +/- 1.1% compared with -4.7 +/- 1.0%; P = 0.011). The amount of urinary equol excreted did not relate to the changes in blood lipids. Conclusions: Soy foods reduced serum LDL cholesterol equally in both equol producers and nonproducers. However, in equol producers, similar to 35% of our study population, soy consumption had the added cardiovascular benefit of maintaining higher HDL-cholesterol concentrations than those seen in equol nonproducers. This trial was registered at clinicaltrials.gov as NCT00877825 (study 1), NCT00516594 (study 2), and NCT00256516 (study 3). Am J Clin Nutr 2012; 95: 564-71.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available